Jeffrey S. Weber, Reinhard Dummer, Veerle de Pril, Celeste Lebbé, F. Stephen Hodi and for the MDX010-20 Investigators Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab Cancer 119
Version of Record online: 7 FEB 2013 | DOI: 10.1002/cncr.27969
In the phase 3 MDX010-20 trial, treatment with ipilimumab resulted in a characteristic spectrum of adverse events of special interest, consistent with its immune-based mechanism of action. Most ipilimumab-associated adverse events developed within 12 weeks of initial dosing and could be managed using published algorithms.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field